Recently, Shanghai UnionClin Co., Ltd. signed a strategic cooperation agreement with Chongqing University Cancer Hospital regarding the development and application services of an innovative oncology drug clinical study system for the Phase I ward. UnionClin will provide development and application services for the innovative oncology drug clinical study system in the Phase I ward of Chongqing University Cancer Hospital. Before the official launch of the project, a successful trial run was conducted, earning high recognition from the hospital. In the future, UnionClin and Chongqing University Cancer Hospital will engage in more exchanges and cooperation in early clinical study projects of innovative oncology drugs and information system construction.

At the signing ceremony, Hong Zhou, Deputy Director of Chongqing University Cancer Hospital, Yongsheng Li, Director of the Department of Medical Oncology and Phase I Ward, Junlin Wang, Founder and Chairman of UnionClin, and others attended and delivered speeches. The ceremony was hosted by Xia Chen, Director of the Clinical Research Center of Chongqing University Cancer Hospital. Hong Zhou, Deputy Director of Chongqing University Cancer Hospital, constructively proposed the expectation to further cooperate with UnionClin in leading the construction work of the Chongqing Cancer Center.

Yongsheng Li (right), Director of the Department of Medical Oncology and Phase I Ward at Chongqing University Cancer Hospital, and Junlin Wang (left), Founder and Chairman of UnionClin

On-site Photos of the Signing Ceremony

About Chongqing University Cancer Hospital

Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing Cancer Institute, Chongqing Cancer Center is a national Level 3 Grade A specialized cancer hospital integrating medical treatment, teaching, scientific research, prevention and rehabilitation. It is a member unit of the International Union Against Cancer (UICC), a joint construction unit of national cancer medical regional center, a construction unit of national regional traditional Chinese medicine (TCM) tumor diagnosis and treatment center, a construction unit of national difficult disease diagnosis and treatment capacity enhancement project; a national tumor drug clinical trial institution, an expert unit of national tumor quality control center, a core unit of national tumor clinical medical research center, Chongqing tumor clinical medical research center, Chongqing cancer medical quality control center, Chongqing cancer radiotherapy quality control center, Chongqing cancer control office.

About UnionClin

Shanghai UnionClin Co., Ltd., founded in 2017, has a founding team with extensive experience in the entire chain of new drug development from early R&D to commercialization. UnionClin can start from clinical needs, stand in the sponsor's perspective, plan and integrate resources, and help clients succeed. UnionClin upholds the mission of "accelerating clinical studies for new drugs and seeking new life for thousands of patients" and is committed to becoming the preferred partner for clinical studies of innovative oncology drugs. Currently, the team has over 600 members, distributed across more than 25 cities nationwide, and has provided CRO and SMO services for over 100 new drug clinical studies.